Pay in 4 interest-free payments of $5.82 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Participants without type 2 diabetes who received mazdutide 9 mg lost an average of 20.08% of their body weight at week 60
Peptide-based therapeutics, such as semaglutide, have shown efficacy for glycaemic control and weight loss
The immune privilege is maintained by the expression of Fas ligand (FasL) on the surface of disc cells, which induces apoptosis in cells carrying the Fas receptor
Weight loss is only half the tale
Tirzepatide can cause modest increases in heart rate and some patients may experience palpitations, which can be perceived as chest discomfort
The same is true for bariatric surgery, currently the most effective intervention for obesity, which can also drive type 2 diabetes into remission
